Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
PeroxiBiokey
Leuven, Flanders, Belgiumperoxibiokey.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
PeroxiBiokey is a biotechnology company focused on developing novel therapeutics that target peroxisome dysfunction to treat rare genetic diseases and age-related conditions. The company's proprietary platform identifies small molecules capable of restoring or enhancing peroxisomal function, which is critical for lipid metabolism and cellular redox balance. Their lead programs target Zellweger spectrum disorder and X-linked adrenoleukodystrophy, with additional research into neurodegenerative and metabolic diseases. By addressing the underlying organelle dysfunction, PeroxiBiokey aims to provide first-in-class treatments for disorders with high unmet medical needs.
- Therapeutic areas
- NeurologyOphthalmologyRare Diseases
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on PeroxiBiokey.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PeroxiBiokey.